Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
Launched by ARYX THERAPEUTICS · Oct 17, 2006
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
ATI-2042 is being developed as an alternative to amiodarone, which is considered a first-line therapy for patients with atrial fibrillation and is known to have serious side effects. ATI-2042 was designed to have a reduced plasma half-life and a lower volume of distribution, which is expected to result in an improved safety profile. In contrast to amiodarone, ATI-2042 undergoes rapid metabolism via plasma and tissue esterases, which may reduce tissue accumulation and toxicity. The current trial will determine if ATI-2042 retains the efficacy profile of amiodarone without the side effects at...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Proven paroxysmal atrial fibrillation
- • Pacemaker with appropriate AF diagnostics and recording capabilities
- Exclusion Criteria:
- • Known allergy to Amiodarone or previous treatment for severe Amiodarone toxicity
- • Cardioversion within one month of screening
- • Severe left ventricular dysfunction or CHF with NYHA Class III or above
About Aryx Therapeutics
Aryx Therapeutics is a biopharmaceutical company dedicated to the development of innovative therapies aimed at addressing unmet medical needs in various therapeutic areas. With a robust pipeline focusing on novel drug candidates, Aryx leverages advanced scientific research and cutting-edge technology to enhance patient outcomes. Committed to rigorous clinical trials and regulatory compliance, the company collaborates with healthcare professionals and research institutions to bring safe and effective treatments to market, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Larkspur, California, United States
Aurora, Colorado, United States
Hollywood, Florida, United States
Jacksonville Beach, Florida, United States
Atlanta, Georgia, United States
Marietta, Georgia, United States
Chicago, Illinois, United States
Towson, Maryland, United States
Saginaw, Michigan, United States
Minneapolis, Minnesota, United States
St. Louis, Missouri, United States
Lincoln, Nebraska, United States
Warren, New Jersey, United States
Albuquerque, New Mexico, United States
Buffalo, New York, United States
Hershey, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Charleston, South Carolina, United States
Nashville, Tennessee, United States
Austin, Texas, United States
Houston, Texas, United States
Burlington, Vermont, United States
Newport News, Virginia, United States
Edmonton, Alberta, Canada
Campbell River, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
London, Ontario, Canada
Niagara Falls, Ontario, Canada
Ottawa, Ontario, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Sherbrooke, Quebec, Canada
Terrebonne, Quebec, Canada
Patients applied
Trial Officials
Michael Ezekowitz, MBChB, PhD
Study Chair
Main Line Health
Olga Bandman, MD
Study Director
ARYx Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials